The figure shows an oral disintegrating tablet (uncoated tablet) containing enteric granules of a proton pump inhibitor (Therapeutic agent for peptic ulcer) which is currently widely sold in Japan and abroad. In addition to the therapeutic effect, high reputation of the formulation characteristics from clinical sites has been earned.
SPERA provides CMC solutions from early-stage through new drug application.
Contact USpage top